Mustafa R, et al. Clinical trials in nephrology: An updated systematic review of ClinicalTrials.gov. Kidney Week 2019; FR-PO1199. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3237149

• PubMed
Mustafa R, Clinical trials in nephrology: An updated systematic review of ClinicalTrials.gov. Kidney Week 2019; FR-PO1199. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3237149)| false
• Search Google Scholar
• Export Citation

Levin A, et al. Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 2017; 390:1888–1917. doi: 10.1016/S0140-6736(17)30788-2

• PubMed
Levin A, Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 2017; 390:1888–1917. doi: 10.1016/S0140-6736(17)30788-2)| false
• Search Google Scholar
• Export Citation

Evangelidis N, et al. Developing a set of core outcomes for trials in hemodialysis: An international Delphi survey. Am J Kidney Dis 2017; 70:464–475. doi: 10.1053/j.ajkd.2016.11.029

• PubMed
Evangelidis N, Developing a set of core outcomes for trials in hemodialysis: An international Delphi survey. Am J Kidney Dis 2017; 70:464–475. doi: 10.1053/j.ajkd.2016.11.029)| false
• Search Google Scholar
• Export Citation

Flythe JE, et al. Cultivating a research-ready dialysis community. J Am Soc Nephrol 2019; 30:375–380. doi: 10.1681/ASN.2018101059

• PubMed
Flythe JE, Cultivating a research-ready dialysis community. J Am Soc Nephrol 2019; 30:375–380. doi: 10.1681/ASN.2018101059)| false
• Search Google Scholar
• Export Citation

Thompson A, et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015; 26:2930–2937. doi: 10.1681/ASN.2015010091

• PubMed
Thompson A, Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015; 26:2930–2937. doi: 10.1681/ASN.2015010091)| false
• Search Google Scholar
• Export Citation

Allon M, et al. Recommended clinical trial end points for dialysis catheters. Clin J Am Soc Nephrol 2018; 13:495–500. doi: 10.2215/CJN.12011116

• PubMed
Allon M, Recommended clinical trial end points for dialysis catheters. Clin J Am Soc Nephrol 2018; 13:495–500. doi: 10.2215/CJN.12011116)| false
• Search Google Scholar
• Export Citation

Smith KA, et al. Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 2019; 73:533–541. doi: 10.1053/j.ajkd.2018.11.001

• PubMed
Smith KA, Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 2019; 73:533–541. doi: 10.1053/j.ajkd.2018.11.001)| false
• Search Google Scholar
• Export Citation

Levey AS, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020; 75:84–104. doi: 10.1053/j.ajkd.2019.06.009

• PubMed
Levey AS, Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020; 75:84–104. doi: 10.1053/j.ajkd.2019.06.009)| false
• Search Google Scholar
• Export Citation

Levey AS, et al. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:P821–P835. doi: 10.1053/j.ajkd.2014.07.030

• PubMed
Levey AS, GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:P821–P835. doi: 10.1053/j.ajkd.2014.07.030)| false
• Search Google Scholar
• Export Citation

Beathard GA, et al. Definitions and end points for interventional studies for arteriovenous dialysis access. Clin J Am Soc Nephrol 2018; 13:501–512. doi: 10.2215/CJN.11531116

• PubMed
Beathard GA, Definitions and end points for interventional studies for arteriovenous dialysis access. Clin J Am Soc Nephrol 2018; 13:501–512. doi: 10.2215/CJN.11531116)| false
• Search Google Scholar
• Export Citation

Mackay M, et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 2019; 71:411–419. doi: 10.1002/art.40724

• PubMed
Mackay M, Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 2019; 71:411–419. doi: 10.1002/art.40724)| false
• Search Google Scholar
• Export Citation

Thompson A, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469–481. doi: 10.2215/CJN.08600718

• PubMed
Thompson A, Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469–481. doi: 10.2215/CJN.08600718)| false
• Search Google Scholar
• Export Citation